RxDoctor Payments Data

Ronald Oglesby, DO

Family Medicine · Broken Arrow, OKNPI 1578595955

Payments from drug & device makers

$10,586in general payments, 2019–2025

Across 675 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$870
  • Lilly USA, LLC$851
  • GSK$782
  • Bayer$743
  • AstraZeneca$694
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$10,578100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,586 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$89,647
Medicare patients
234
Services billed
1,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$104,434
OzempicSemaglutide63$76,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$75,216
JardianceEmpagliflozin42$60,549
FarxigaDapagliflozin Propanediol43$57,563
MounjaroTirzepatide38$37,302
TrulicityDulaglutide24$27,416
JanuviaSitagliptin Phosphate22$25,340
MyrbetriqMirabegron27$22,809
VraylarCariprazine Hcl11$18,522
XareltoRivaroxaban19$17,575
TrintellixVortioxetine Hydrobromide18$14,868
Bydureon BciseExenatide Microspheres13$11,082
LinzessLinaclotide11$8,005
GemtesaVibegron12$6,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$870$104,434102 claims
GSKTrelegy Ellipta, Anoro Ellipta$782$80,45793 claims
Novo NordiskOzempic$1,632$76,49063 claims
Lilly USA, LLCMounjaro, Trulicity$851$64,71862 claims
Boehringer IngelheimJardiance$148$60,54942 claims
AstraZenecaFarxiga$694$57,56343 claims
AbbVieVraylar, Linzess, Synthroid$598$28,96964 claims
MerckJanuvia$338$25,34022 claims
Astellas Pharma US IncMyrbetriq$251$22,80927 claims
Johnson & JohnsonXarelto$167$17,57519 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$115$14,86818 claims
Sumitomo Pharma America, Inc.Gemtesa$71$6,99712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →